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Objective: This study is to investigate the role of miR-143 expression in cervical squamous cell carcinoma (SCC).
Methods: The expression level of miR-143 was examined by quantitative real-time PCR. Human papillomavirus
(HPV) genotype was detected by HPV genotype detection kit. The expression level of bcl-2 was detected by
immunohistochemistry.
Results: The positive rate of HPV was 78% in the patients of cervical SCC. The most prevalent genotype was HPV16,
with a positive rate of 42%. The expression level of miR-143 was significantly lower in the cervical SCC tissues than
that in the normal cervical tissues (Z = −2.180, P = 0.029). Down-regulated miR-143 expression was associated with
tumor size, lymph node metastasis and HPV16 infection in cervical cancer patients. No significant associations were
found between the expression levels of miR-143 and age, clinical stage, differentiation or lymph vascular space
invasion. And, in cervical SCC patients after treatment with Taxol chemotherapy, the expression level of miR-143 was
higher and the positive expression of bcl-2 protein was lower. However, the differences in expression changes of
miR-143 and bcl-2 were not statistically significant (miR-143, Z = −0.763, P = 0.446; bcl-2 protein, χ2 = 2.277, P = 0.131).
Conclusion: Down-regulated miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in
cervical SCC, but miR-143 does not participate in the Taxol sensitivity response.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1401279451112150.Introduction
Cervical cancer is caused by the activation of oncogenes
and the inactivation of tumor suppressor genes, which
are induced by carcinogens through different mecha-
nisms. Persistent infection of the human papillomavirus
(HPV) is an important factor causing cervical cancer.
Genes of E6 and E7 of HPV are able to inactivate the
cellular tumor suppressor genes and induce the over ex-
pression of the anti-apoptotic genes. Besides HPV, fac-
tors from host cells are also critical in the process of
cervical malignant transformation. MicroRNAs (miR-
NAs) are a class of small, endogenous, single-stranded,
non-coding RNA molecules, which can regulate cell pro-
liferation, differentiation and apoptosis through targeting* Correspondence: chenyanxiacyx@sina.cn
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unless otherwise stated.specific genes. Thus they might be involved in carcino-
genesis or tumor suppression. Abnormal expression of
miR-143 is observed in many types of tumors, and it is
involved in the tumor responses to chemotherapy [1].
Bcl-2 is the major target of miR-143. It is reported that
HPV infection may alter miRNA profiles in squamous
cell carcinoma of the head and neck cell lines [2]. Lajer
et al. found that the miR-143/miR-145 may be involved
in the pathogenesis of HPV-related head and neck can-
cer and cervical cancer [3]. Wang et al. showed that
miR-143 and miR-145 expression was down-regulated in
cervical cancer tissues and HPV-infected raft tissues
with pre-neoplastic lesions. Overexpression of miR-143
and miR-145 suppressed HeLa cell growth. Their findings
suggest that down regulation of miR-143 and miR-145
may favor cell growth of cervical cancer [4]. Georgios
et al. found that miR-143 expression did not correlate withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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an important role in cervical cancer.
Neoadjuvant chemotherapy (NACT) provides surgical
opportunities for some patients, with enhanced efficacy
of surgery and radiotherapy [6]. It is reported that miR-
NAs are involved in drug resistance of cancer cells. For
example, Zhang et al. studied the miRNA signature in
stage II colon cancer using miRNA microarrays. They
found that six miRNAs, including miR-21-5p, miR-20a-
5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-
215, might be able to predict which patients benefit from
adjuvant chemotherapy [7]. Borralho et al. reported that
miR-143 increased the sensitivity of HCT116 human
colorectal cancer cells to 5-fluorouracil, probably through
extracellular-regulated protein kinase 5/nuclear factor-
kappaB regulated pathways [8]. Xu et al. found that miR-
143 enhanced the sensitivity of prostate cancer cells to
docetaxel [9]. However, little is known about the role of
miR-143 in modulating the cervical cancer cell response
to Taxol.
The incidence rate of cervical cancer among the
Uighur in the Xinjiang Uygur Autonomous Region is
three to four times of that in Han race. And there are
more cases in the Xinjiang Uygur Autonomous Region
with advanced stages of cervical cancer. This study aims
to investigate the role of miR-143 expression in cervical
SCC through detecting miR-143 expression, analyzing
the relationship between miR-143 expression and clinical
pathological features of cervical cancer, and assessing
the sensitivity of miR-143 and bcl-2 expression to Taxol
treatment. Therefore, in this study, the miR-143 expres-
sion levels in cervical tumors infected with different
HPV genotypes and in the cervical cancer tissues before
and after NACT treatment were detected. Then the rela-
tionship between the miR-143 and the clinical and
pathological features of cervical squamous cell carcin-
oma (SCC) in Uighur was analyzed. Additionally, the ex-




Paraffin-embedded cervical tissues from 97 patients were
collected in this study. The 97 patients were hospitalized
from June 2010 to January 2012 in First Teaching Hos-
pital of Xinjiang Medical University. Among them, 20
control patients had normal cervixes and 77 patients
had cervical SCC. Patients with cervical SCC were newly
diagnosed SCC cases, and did not receive radiotherapy
or chemotherapy before surgery. The clinical patho-
logical data of the 77 cervical SCC patients were shown
in Table 1. The clinical data for 20 control patients was
shown in Table 2. Exfoliated cervical cells were collected
and the genotypes of HPV were classified by blinddetection. Among the patients with cervical SCC, there
were 59 patients who underwent radical hysterectomy
and pelvic lymphadenectomy, and 18 patients who
underwent cervical biopsy. And there were 16 cases at
stage I, 43 cases at stage II, and 18 cases at stage III-IV;
27 well differentiated cases and 50 moderate and poor
differentiated cases; 23 patients with tumor diameters >
4 cm, and 54 patients with tumor diameters ≤ 4 cm; 43
cases without lymph node metastasis, and 16 cases with
lymph node metastasis; 13 cases of lymph vascular space
invasion (LVSI), and 46 cases without LVSI. The normal
cervical tissues were collected from patients who under-
went uterus hysterectomy because of myoma. Ages of
the patients with normal cervixes ranged from 30 to
76 years old, with the mean age of 45 years old; and
those of the cervical SCC patients ranged from 27 to
80 years old, with the mean age of 47 years old. There was
no statistical significance in age between patients with
normal cervical tissues and patients with cervical SCC.
Fresh cervical tissues from another 34 cervical SCC
patients who were hospitalized in the hospital from
January 2012 to December 2012 for pre-surgical chemo-
therapy were also selected. They were diagnosed as stage
I b2 – II b cervical SCC by at least two co-chief physi-
cians. They were treated with NACT before surgery.
Clinical data of 34 cervical SCC patients who received
NACT before surgery were shown in Table 3. A matched
pair of tissue samples from the same patient prior to
chemotherapy and after chemotherapy was collected
from all the 34 patients. Each sample was divided into
two parts: one part was put into liquid nitrogen within
10 minutes after separation, and then stored at −80°C,
and the other part was used for pathological diagnosis
after hematoxylin-eosin (HE) staining. The ages of cer-
vical SCC patients with chemotherapy ranged from 32
to 67 years old, with a mean age of 47.5 years old.
The informed consents were obtained from all pa-
tients, and the study was approved by the ethics com-
mittee of Xinjiang Medical University. Female patients
with other malignant tumors, gestation, breast-feeding,
or complications who were intolerant to chemotherapy
were excluded. Clinical staging was performed according
to the 2009 International Federation of Gynecology and
Obstetrics (FIGO) staging criteria, and the images were
read by two pathology experts independently based on
the WHO histopathological criteria.
Reagents
RNeasy FFPE Kit (cat. no. 73504) was purchased from
QIAGEN Ltd (Hilden, Germany). Trizol was obtained
from Invitrogen CO., Ltd. (Carlsbad, California, USA).
Reverse transcription Kit (#K1622) and real-time fluor-
escent quantitative PCR Mix (#K0221) were purchased
from Thermo Fisher Scientific Inc (Vilnius, Lithuania).

















1 46 2010.7.2 Stage I Well differentiation No ≤ 4 No Single/multiple HPV16 infection
2 44 2010.7.5 Stage II Moderate and poor differentiation No ≤ 4 No Single/multiple HPV16 infection
3 35 2010.7.13 Stage I Well differentiation No ≤ 4 Yes Negative
4 39 2010.7.26 Stage II Moderate and poor differentiation No ≤ 4 No Negative
5 38 2010.7.30 Stage I Moderate and poor differentiation Yes > 4 No Other HPV type
6 30 2010.8.2 Stage I Moderate and poor differentiation No ≤ 4 No Single/multiple HPV16 infection
7 47 2010.8.5 Stage III-IV Well differentiation Yes ≤ 4 No Single/multiple HPV16 infection
8 41 2010.8.12 Stage II Well differentiation No > 4 No Single/multiple HPV16 infection
9 44 2010.8.23 Stage II Moderate and poor differentiation No ≤ 4 No Negative
10 38 2010.8.23 Stage III-IV Moderate and poor differentiation No ≤ 4 No Other HPV type
11 27 2010.8.25 Stage III-IV Well differentiation No ≤ 4 No Other HPV type
12 48 2010.8.30 Stage I Moderate and poor differentiation No ≤ 4 No Negative
13 42 2010.9.7 Stage II Well differentiation Yes > 4 Yes Single/multiple HPV16 infection
14 44 2010.9.10 Stage I Moderate and poor differentiation No ≤ 4 No Negative
15 42 2010.9.17 Stage I Moderate and poor differentiation No > 4 No Single/multiple HPV16 infection
16 45 2010.9.27 Stage II Moderate and poor differentiation No > 4 No Single/multiple HPV16 infection
17 44 2010.9.28 Stage II Moderate and poor differentiation No 1 No Single/multiple HPV16 infection
18 42 2010.9.28 Stage II Moderate and poor differentiation No ≤ 4 No Other HPV type
19 47 2010.9.30 Stage II Moderate and poor differentiation Yes > 4 No Single/multiple HPV16 infection
20 39 2010.10.18 Stage I Moderate and poor differentiation No ≤ 4 No Single/multiple HPV16 infection
21 48 2010.10.28 Stage II Well differentiation No ≤ 4 No Single/multiple HPV16 infection
22 36 2010.11.2 Stage II Moderate and poor differentiation Yes > 4 Yes Other HPV type
23 43 2010.11.16 Stage II Moderate and poor differentiation No ≤ 4 No Other HPV type
24 34 2010.11.24 Stage I Moderate and poor differentiation No ≤ 4 No Other HPV type
25 46 2010.12.10 Stage III-IV Well differentiation — > 4 — Other HPV type
26 45 2010.12.16 Stage II Well differentiation — ≤ 4 — Other HPV type
27 32 2010.12.27 Stage III-IV Well differentiation — ≤ 4 — Single/multiple HPV16 infection
28 27 2011.1.7 Stage III-IV Well differentiation — > 4 — Single/multiple HPV16 infection
29 40 2011.1.14 Stage III-IV Well differentiation — ≤ 4 — Single/multiple HPV16 infection
30 29 2011.1.17 Stage III-IV Well differentiation — ≤ 4 — Other HPV type
31 42 2011.2.21 Stage I Well differentiation — ≤ 4 — Single/multiple HPV16 infection
32 35 2011.2.25 Stage I Well differentiation — ≤ 4 — Negative
33 29 2011.3.1 Stage III-IV Well differentiation — > 4 — Negative
34 38 2011.3.10 Stage III-IV Well differentiation — ≤ 4 — Other HPV type
35 41 2011.3.15 Stage III-IV Well differentiation — ≤ 4 — Single/multiple HPV16 infection
36 28 2011.3.19 Stage II Moderate and poor differentiation — ≤ 4 — Single/multiple HPV16 infection
37 40 2011.3.21 Stage II Moderate and poor differentiation — > 4 — Negative
38 37 2011.4.9 Stage II Moderate and poor differentiation — ≤ 4 — Other HPV type
39 43 2011.4.13 Stage II Moderate and poor differentiation — > 4 — Single/multiple HPV16 infection
40 29 2011.4.18 Stage II Well differentiation — > 4 — Other HPV type
41 43 2011.4.21 Stage II Moderate and poor differentiation — > 4 — Single/multiple HPV16 infection
42 53 2011.4.22 Stage III-IV Moderate and poor differentiation No > 4 Yes Negative
43 66 2011.5.10 Stage III-IV Moderate and poor differentiation No ≤ 4 No Other HPV type
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Table 1 Clinical pathological data of cervical SCC patients (n = 77) (Continued)
44 54 2011.5.16 Stage III-IV Moderate and poor differentiation No ≤ 4 No Other HPV type
45 56 2011.5.23 Stage II Moderate and poor differentiation No ≤ 4 No Other HPV type
46 57 2011.5.25 Stage II Moderate and poor differentiation Yes ≤ 4 Yes Other HPV type
47 54 2011.5.30 Stage II Well differentiation No ≤ 4 No Other HPV type
48 54 2011.6.3 Stage III-IV Moderate and poor differentiation Yes ≤ 4 No Other HPV type
49 66 2011.6.10 Stage II Moderate and poor differentiation Yes ≤ 4 No Other HPV type
50 77 2011.6.14 Stage III-IV Moderate and poor differentiation Yes ≤ 4 No Single/multiple HPV16 infection
51 50 2011.6.15 Stage II Well differentiation No ≤ 4 No Single/multiple HPV16 infection
52 68 2011.6.20 Stage II Well differentiation No ≤ 4 No Negative
53 61 2011.7.11 Stage II Moderate and poor differentiation No ≤ 4 Yes Negative
54 69 2011.7.15 Stage II Moderate and poor differentiation No ≤ 4 Yes Other HPV type
55 49 2011.7.18 Stage II Moderate and poor differentiation No > 4 No Single/multiple HPV16 infection
56 49 2011.7.18 Stage II Moderate and poor differentiation Yes > 4 Yes Negative
57 54 2011.8.1 Stage II Moderate and poor differentiation No ≤ 4 No Single/multiple HPV16 infection
58 51 2011.8.25 Stage III-IV Well differentiation No ≤ 4 No Single/multiple HPV16 infection
59 56 2011.8.26 Stage II Moderate and poor differentiation Yes ≤ 4 Yes Single/multiple HPV16 infection
60 53 2011.913 Stage II Moderate and poor differentiation No > 4 No Single/multiple HPV16 infection
61 50 2011.9.16 Stage I Well differentiation No ≤ 4 No Other HPV type
62 51 2011.9.21 Stage II Moderate and poor differentiation No ≤ 4 No Single/multiple HPV16 infection
63 49 2011.9.23 Stage I Well differentiation No ≤ 4 No Negative
64 57 2011.10.14 Stage II Moderate and poor differentiation No ≤ 4 Yes Negative
65 61 2011.11.2 Stage II Well differentiation No > 4 No Other HPV type
66 52 2011.11.15 Stage II Moderate and poor differentiation No ≤ 4 No Negative
67 50 2011.11.17 Stage II Moderate and poor differentiation Yes > 4 No Single/multiple HPV16 infection
68 56 2011.11.21 Stage I Moderate and poor differentiation No ≤ 4 Yes Negative
69 64 2011.11.25 Stage I Moderate and poor differentiation No ≤ 4 No Single/multiple HPV16 infection
70 80 2011.12.2 Stage II Moderate and poor differentiation No ≤ 4 Yes Single/multiple HPV16 infection
71 61 2011.12.2 Stage II Well differentiation Yes ≤ 4 No Other HPV type
72 49 2011.12.5 Stage II Moderate and poor differentiation No > 4 No Other HPV type
73 49 2011.12.16 Stage II Moderate and poor differentiation Yes ≤ 4 No Other HPV type
74 59 2012.1.10 Stage II Moderate and poor differentiation Yes ≤ 4 No Other HPV type
75 50 2012.1.13 Stage II Moderate and poor differentiation Yes > 4 No Single/multiple HPV16 infection
76 67 2012.1.16 Stage I Moderate and poor differentiation No ≤ 4 Yes Other HPV type
77 58 2012.1.19 Stage III-IV Moderate and poor differentiation — ≤ 4 — Negative
Note: SCC, squamous cell carcinoma; LVSI, lymph vascular space invasion. “—” indicates that no such examination was performed.
Among the 77 cervical patients, 59 cases received extensive hysterectomy and pelvic lymphadenectomy and 18 cases were not treated with surgery. Lymph node
metastasis and LVSI were not examined in these 18 cases who were not treated with surgery.
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U6 and miR-143 were synthesized by Taihe Biotechnol-
ogy Co., Ltd. (Beijing, China). The bcl-2 antibody (sc-
7382) was purchased from Santa Cruz Biotechnology Inc
(California, USA). The universal secondary antibody
(PV-6000), goat serum and diaminobenzidine (DAB)
reagent were all purchased from Beijing Zhong Shan-
Golden Bridge Biological Technology CO., Ltd. (Beijing,
China). Cell lysis buffer and the HPV genotype detection
kit were products from Chaozhou Kaipu BiochemistryCo. Ltd. (Chaozhou, China). ABI7500 real-time PCR sys-
tem was purchased from Applied Biosystems, Inc. (New
York, USA), and the OLYMPUS microscopy was from
Olympus optical Co., Ltd. (Tokyo, Japan).
HPV genotype detection
Exfoliated cervical cell specimens were obtained by cer-
vical brush clockwise rotation for five turns at the cervix.
DNA was extracted from these specimens for determin-
ation of HPV genotypes. For DNA amplication, 1 μl of
Table 2 Clinical data of 20 control patients with normal









1 43 2010.7.14 11 42 2011.5.13
2 32 2010.7.29 12 40 2011.6.16
3 50 2010.8.13 13 39 2011.7.15
4 30 2010.9.15 14 44 2011.8.16
5 37 2010.9.16 15 66 2011.9.13
6 41 2010.10.19 16 31 2011.9.16
7 40 2010.12.17 17 45 2011.10.18
8 47 2011.1.17 18 76 2011.11.21
9 59 2011.3.17 19 42 2011.12.2
10 63 2011.4.20 20 50 2012.1.10
Table 3 Clinical data of 34 cervical SCC patients who
received NACT before surgery (n = 34)
Patients Age (year) Selection date Clinical stage NACT efficacy
1 45 2012.1.27 Stage Ib2 Effective
2 34 2012.2.4 Stage IIa Effective
3 36 2012.3.12 Stage IIb Effective
4 47 2012.4.15 Stage Ib2 Not effective
5 57 2012.4.17 Stage Ib2 Effective
6 39 2012.5.15 Stage IIa Effective
7 45 2012.5.18 Stage IIa Effective
8 42 2012.6.3 Stage IIb Not effective
9 32 2012.6.17 Stage Ib2 Effective
10 66 2012.6.26 Stage IIa Not effective
11 59 2012.7.14 Stage IIb Not effective
12 46 2012.8.4 Stage Ib2 Effective
13 49 2012.8.15 Stage IIa Not effective
14 51 2012.8.24 Stage Ib2 Effective
15 35 2012.8.29 Stage Ib2 Effective
16 38 2012.9.16 Stage IIa Not effective
17 40 2012.9.19 Stage Ib2 Effective
18 43 2012.10.7 Stage IIa Effective
19 58 2012.10.11 Stage IIb Effective
20 63 2012.10.17 Stage IIa Not effective
21 53 2012.10.19 Stage Ib2 Effective
22 48 2012.10.25 Stage Ib2 Effective
23 43 2012.10.28 Stage IIa Effective
24 45 2012.11.1 Stage IIb Not effective
25 44 2012.11.5 Stage IIa Effective
26 61 2012.11.16 Stage Ib2 Not effective
27 39 2012.11.23 Stage IIa Effective
28 67 2012.11.25 Stage IIa Effective
29 56 2012.11.30 Stage Ib2 Effective
30 44 2012.12.2 Stage Ib2 Effective
31 33 2012.12.10 Stage IIa Not effective
32 54 2012.12.15 Stage Ib2 Effective
33 57 2012.12.19 Stage IIa Effective
34 49 2012.12.22 Stage Ib2 Effective
Note: SCC, squamous cell carcinoma. NACT, neoadjuvant chemotherapy.
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ing Taq polymerase, dNTP and primers) were mixed to-
gether to form a 25 μl system. Then PCR products were
hybridized to films according to the manufacturer’s in-
struction. During the color development, 0.5 ml of alka-
line phosphatase chromogenic substrates were added
and incubated for 2–5 minutes at 36°C. Results were an-
alyzed within 1 hour after color development through
visual observation. Positive points were defined as clear
visible blue purple dots. There were one PCR reaction
control and one hybridization coloration quality control
point on each film. The HPV genotypes were determined
based on their distribution sites on the films, including
21 HPV genotypes of 6, 11, 16, 18, 31, 33, 35, 39, 42, 43,
44, 45, 51, 52, 53, 56, 58, 59, 66, 68 and 81 (CP8304).
Reverse transcription and real-time PCR
Total RNAs of paraffin-embedded cervical tissues were
extracted according to the RNeasy FFPE kit’s instruction,
while those of the fresh cervical tissues were extracted
by Trizol. U6 was used as internal standard control. The
volume of reverse transcription reaction system was
20 μl, containing 200 ng of total RNAs, 1 μl of reverse
transcription primers diluted to 12 μl with water, 4 μl of
buffer, 1 μl of RNase inhibitor, 2 μl of dNTP and 1 μl of
M-MuLV reverse transcriptase. Reverse transcriptions
were performed. The miR-143-specific primer sequence
for reverse transcription was: 5’-GTCGTATCCAGTGC
GTGTCGTGGAGTCGGCAATTGCACTGGATACGAC
TGAGCTA-3’. The miR-143-specific PCR primer se-
quences for real-time PCR were: forward, 5’-AGTGCGTG
TCGTGGAGT-3’; reverse, 5’-GCCTGAGATGAAGCAC
TGT-3’. The U6 PCR primer sequences were: forward, 5’-
CTCGCTTCGGCAGCACA-3’; reverse, 5’-ACGCTTCA
CGAATTTTGCGT-3’.
Each sample was repeated 3 times. The PCR products
were analyzed by 2.5% agarose gel electrophoresis. Thenumber of cycles for each reaction tube to reach the pre-
established fluorescence threshold was recorded as Ct
value, and the relative expression quantities of miR-143
were presented as N = 2-ΔΔCt. For the comparison of cervical
SCC group to normal cervix group, ΔΔCt = (CtmiR-143-
CtU6)SCC - (average CtmiR-143 - average CtU6)normal; For the
comparison of cervical SCC group after chemotherapy
to the cervical SCC group before chemotherapy, ΔΔCt =
(CtmiR-143 - CtU6)after - (CtmiR-143 - CtU6)before.
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Immunohistochemistry was performed in fresh cervical
tissues to detect the expression of Bcl-2. Briefly, slices
(4 μm in thickness) were incubated in 3% H2O2 for
10 minutes at room temperature to block endogenous
peroxidase. Bcl-2 mouse monoclonal antibody (1: 200)
was added and kept at 4°C overnight, and then incu-
bated for 1 hour at room temperature. Then, the univer-
sal IgG antibody conjugated with HRP was added and
incubated at 37°C for 25 minutes. DAB solution was
used for color development, and the staining results
were observed under microscopy. Finally, the slices were
counterstained with hematoxylin for 10 minutes, differ-
entiated with hydrochloric acid ethanol, and then
mounted with neutral gum after dehydration. The slices
were observed under microscopy. Bcl-2 positive breast
cancer tissue was used as bcl-2 positive control and PBS
instead of the primary antibody was used as negative
control. Positive staining cells were stained brown-
yellow or yellow in the cytoplasm or cell membrane. Five
fields were randomly selected on each slice and 200 cells
were counted in each field. Then the percentage of posi-
tive cells in all counted cells was calculated. Negative
staining was defined as no positive staining on the whole
slice or the percentage of positive cells < 10% and posi-
tive staining was defined as the percentage of positive
cells > 10%.
NACT
The chemotherapy regimen included Taxol (175 mg/m2)
and carboplatin (dosage of which was calculated based
on the age, serum creatinine and weight of the patient).
Taxol and carboplatin were administered within one day.
Two courses of treatments were taken with an interval
of 3 weeks, and surgery was performed 2 – 3 weeks after
the chemotherapy. The tumor sizes of the patientsFigure 1 Comparison of miR-143 expression in normal cervical tissue
metastasis. Real time PCR was conducted to detect miR-143 expression. R
(A) Comparison of miR-143 expression in normal cervical tissue (NT) and ce
larger tumor (tumor diameter > 4 cm). (B) Comparison of miR-143 expressio
lymph node (LN) metastasis.treated with NACT were measured through gynecological
and imaging examinations before chemotherapy, and
measured by pathological examinations after surgery. Ac-
cording to the WHO criteria, effectiveness of treatment
was defined as the follows: complete remission, tumor is
completely disappeared; partial remission, the tumor size
decreases more than 50%; stable or no change, the tumor
size increases or decreases no more than 25%, and no new
lesions appear; progression, new lesions appear or the size
of tumor increases more than 25% during the treatment.
Complete and partial remissions were defined as effective.
Statistical analysis
Data were processed using SPSS 17.0 software. The data
was non-normal distribution and thus median and quar-
tile were used. Mann–Whitney U test was used for com-
parison between two groups, while Kruskal-Wallis H test
was used for comparison among multiple groups. P < 0.05
was considered as statistically significant.
Results
The miR-143 expression in normal cervix and cervical SCC
tissues and its correlation with clinical pathological
features of cervical SCC
To determine the expression levels of miR-143 in nor-
mal cervix and cervical SCC, real time PCR was per-
formed. Quantitative results of miR-143 expression and
its correlation with clinical pathological features of
cervical SCC were shown in Figure 1 and Table 4. In
comparison with normal cervix, the expression level of
miR-143 in cervical SCC group was decreased, and the
difference was statistically significant (Z = −2.180, P =
0.029). The expression of miR-143 in cervical SCC with
tumor diameter ≤ 4 cm was significantly higher than that
with tumor diameter > 4 cm (Z = −2.705, P = 0.007)
(Table 4 and Figure 1A). And, miR-143 expression leveland cervical SCC tissue with different tumor size and lymph node
elative expression of miR-143 was calculated using the 2-ΔΔCt method.
rvical SCC tissue with smaller tumor (tumor diameter≤ 4 cm) and
n in normal cervical tissue (NT) and cervical SCC tissue with or without
Table 4 Correlation between miR-143 expression and
cervical SCC clinical pathological features
Clinical characters Cases
(n)
miR-143 expression Z P
Cervical SCC −2.180 0.029*
No 20 1.000 (0.241-1.878)
Yes 77 0.280 (0.059-1.050)
Age (years old) −1.236 0.217
≤ 50 41 0.259 (0.143-0.707)
> 50 36 0.337 (0.167-1.092)
Clinical Stage 2.673 0.263
I 16 0.387 (0.176-1.258)
II 43 0.268 (0.131-0.698)
III-IV 18 0.287 (0.155-0.905)
Pathological Grade −1.142 0.253




Lymph node metastasis −2.293 0.022*
No 43 0.578 (0.209-1.384)
Yes 16 0.175 (0.103-0.544)
Tumor diameter −2.705 0.007*
≤ 4 cm (smaller tumor) 54 0.345 (0.112-1.490)
> 4 cm (larger tumor) 23 0.125 (0.103-0.459)
LVSI −0.567 0.571
No 46 0.294 (0.159-1.075)
Yes 13 0.607 (0.293-1.501)
HPV infection 9.050 0.011*
HPV negative 17 1.053 (0.289-1.412)
HPV16 infection
(single or multiple)△
32 0.230 (0.105-0.496) −2.647 0.008*
Other genotype
HPV infection△
28 0.524 (0.109-1.233) −1.651 0.099
Note: *P < 0.05. △in comparison with HPV negative group.
SCC, squamous cell carcinoma; LVSI, lymph vascular space invasion.
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higher than that with lymph node metastasis and the dif-
ference was also statistically significant (Z = −2.293, P =
0.022) (Table 4 and Figure 1B).
In addition, the HPV genotype was detected. In cer-
vical SCC patients, there were 60 HPV positive patients
(78%). Among them, 32 were infected by HPV16 (42%),
including 25 single infections (33%) and 7 mixed infec-
tions (9%), and 28 patients were infected by other HPV
genotypes, in which HPV18, HPV52 and HPV58 were
the major genotypes. Statistically, the expression of miR-
143 in HPV negative cervical SCC patients was signifi-
cantly higher than that in HPV positive cervical SCC
patients (Z =9.050, P = 0.011) (Table 4). Meanwhile, in
comparison with HPV negative cervical SCC patients,the expression of miR-143 in the HPV16 positive cer-
vical SCC patients was significantly lower (Z = −2.647,
P = 0.008) whereas in cervical SCC patients infected with
other HPV genotypes, the difference was not significant
(Z = −1.651, P = 0.099). However, the miR-143 expres-
sion levels between ages, clinical stages, pathological
grades and LVSI were not significantly different.
Collectively, these data suggest that miR-143 expres-
sion in cervical SCC patients was down-regulated and
that it was significantly correlated with lymph node me-
tastasis, tumor diameter and HPV infection, but not
with ages, clinical stages, pathological grades or LVSI.
Evaluation of miR-143 expression as predictor of tumor
size and lymph node metastasis
The specificity and sensitivity of miR-143 evaluation on
tumor size and lymph node metastasis of cervical SCC
were analyzed by receiver operating characteristic (ROC)
curve (Figure 2). Tumor size with tumor diameter >
4 cm was defined as larger tumor and ≤ 4 cm as smaller
tumor. As shown in Figure 2A, the AUC of miR-143 to
differentiate larger tumor from smaller tumor was 0.696
(95% confidence interval: 0.573 - 0.818, P = 0.007). If the
relative expression level of 0.286 was used as the evalu-
ation critical value, the sensitivity and specificity of miR-
143 to differentiate tumor size were 70.5% and 61.0%,
respectively. As shown in Figure 2B, the AUC of miR-
143 to evaluate whether there was lymph node metasta-
sis was 0.690 (95% confidence interval: 0.555 - 0.836,
P = 0.022). If the relative expression value of 0.314 was
used as the evaluation critical value, the sensitivity and
specificity of miR-143 to differentiate whether there was
lymph node metastasis were 75.0% and 60.0%, respect-
ively. Thus miR-143 may be used as an indicator for the
evaluation of tumor size and lymph node metastasis of
cervical SCC, with good specificity and sensitivity.
Expression of miR-143 and its target gene bcl-2 in cervical
SCC before and after NACT
As mentioned in the Materials and methods, Taxol was
used in NACT. To investigate whether miR-143 partici-
pated in the Taxol sensitivity response, we further ana-
lyzed expression of miR-143 and its target gene bcl-2 in
cervical SCC patients underwent NACT before surgery.
For the 34 patients who underwent chemotherapy before
surgery, 5 cases were with complete remissions, 19 cases
were with partial remissions. And the effective rate of
chemotherapy was 70.83% (24/34). The expression of
miR-143 before and after NACT was analyzed by real
time PCR in 24 patients who were treated effectively.
The same tissues without chemotherapy were used as
control. Expression of miR-143 was up-regulated after
NACT treatment, with the relative expression level of
1.35 (0.44 - 4.29). However, there was no statistical
Figure 2 Analysis of miR-143 expression in cervical SCC patients by ROC curve. (A) ROC curve of miR-143 expression in cervical SCC
patients with different tumor diameter. Tumor size with tumor diameter > 4 cm was defined as larger tumor and≤ 4 cm as smaller tumor.
(B) ROC curve of miR-143 expression in cervical SCC patients with and without lymph node (LN) metastasis.
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after NACT (Z = −0.763, P = 0.446) (Figure 3).
The expression of bcl-2 protein before and after
NACT was also analyzed in effective patients with im-
munohistochemistry. Representative immunohistochem-
ical results were shown in Figure 4. Figure 4A and B
showed the positive expression of bcl-2 in fresh cervical
tissues before NACT treatment and after NACT treat-
ment. Bcl-2 positive cells were stained brown-yellow or
yellow in the cytoplasm or cell membrane. Bcl-2 positive
cells were counted and positive expression rate of bcl-2
was calculated. A percentage of bcl-2 positive cells > 10%
was defined as positive bcl-2 expression. Statistically, the
positive expression rate of bcl-2 was 75% (18/24) before
NACT and 54.17% (13/24) after NACT, however, the
difference was not statistically significant (χ2 = 2.277,
P = 0.131) (data not shown).Figure 3 Comparison of the relative miR-143 expression level in cervi
(NACT). Cervical SCC tissues were collected from 24 cervical SCC patients w
expression before and after NACT. Relative expression of miR-143 was calcuThus miR-143 and bcl-2 expression was not signifi-
cantly changed before and after NACT therapy, suggest-
ing that they may not participate in the Taxol sensitivity
response.
Discussion
Some studies indicate that miR-143 is up-regulated in
tumor tissues [10,11]. Also, through inhibition of
FNDC3B, miR-143 promotes the metastasis of hepatic
carcinoma (animal study) to the lung and the metastasis
of prostate cancer cells [12,13]. However, most of the
studies demonstrate that miR-143 is down-regulated in
solid tumor, including esophageal cancer, bladder cancer
and prostate cancer, etc. [14-16]. The target genes of miR-
143 include KRAS, MACC1 and bcl-2, etc. [17-19], which
are involved in the signaling pathways of ERK5 and
MAPK, etc. [20,21]. Among those target genes, bcl-2 is ancal SCC tissues before and after neoadjuvant chemotherapy
ith effective NACT. Real time PCR was performed to detect miR-143
lated using the 2-ΔΔCt method.
Figure 4 Bcl-2 expression analysis in cervical SCC tissues before and after neoadjuvant chemotherapy (NACT). Cervical SCC tissues were
collected from 24 cervical SCC patients with effective NACT. Bcl-2 expression before and after NACT was analyzed by immunohistochemistry.
Representative immunohistochemical results were shown. Positive staining cells were stained brown-yellow or yellow in the cytoplasm or cell
membrane. (A) Positive expression of bcl-2 in the cytoplasm of cervical tissues before NACT. (B) Positive expression of bcl-2 in the cell membrane
of cervical tissues after NACT.
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protein is to inhibit apoptosis by providing cell resistance
to multiple apoptosis-stimulating factors. It is reported
that through targeting bcl-2, miR-181d inhibited neuroglia
cell proliferation and promoted apoptosis [22] while miR-
15b and miR-16 played a role in the drug resistance of
gastric cancer [23].
Our results indicate that miR-143 was significantly
down-regulated in cervical SCC, which was consistent
with previous reports [24,25]. They both found that
miR-143 expression was down-regulated in cervical can-
cer cell lines and tissues. However, the relationship be-
tween miR-143 expression and clinical pathological
features of cervical cancer is rarely studied. In this study,
we also analyzed whether miR-143 expression was re-
lated with clinical pathological features of cervical can-
cer. Our results showed that the expression of miR-143
was related to the lymph node metastasis of cervical
SCC. Expression of miR-143 was significantly lower in
patients with lymph node metastasis than that in pa-
tients without lymph node metastasis. Similar results
were found in esophageal cancer [26], suggesting that
down-regulation of miR-143 might promote the lymph
node metastasis of cancer cells. The ROC curve analysis
showed that the sensitivity and specificity of miR-143 to
evaluate lymph node metastasis were 75% and 60%, re-
spectively. This data suggest that miR-143 may be used
as an indicator for lymph node metastasis evaluation in
clinic, especially as a reference before surgery. Moreover,
our results showed that miR-143 and tumor diameter
was negatively correlated. A previous study also showed
that the expression of miR-143 in the colorectal cancer
tissue with tumor diameter > 5 cm was lower than that
with tumor diameter < 5 cm [27]. The sensitivity and
specificity of miR-143 to evaluate tumor diameter were
70.5% and 61%, respectively. The self-shedding of ex-
ogenous cervical tumor and the underdetermined tumordiameter of endogenous cervical would lower the clinical
staging of tumor and influence the individualized treat-
ment of patients. Ivanov et al. reported that in cervical
cancer at stage Ib2-IIa, the lymph node metastasis rate
and distant metastasis rate were increased as the tumor
size enlarged [28], and there was certain correlation be-
tween tumor metastasis and tumor size. In addition, we
found that the expression of miR-143 was irrelevant to
the age, clinical stage, pathological grade and LVSI of
the SCC patients.
The infection rate of high-risk HPV in cervical cancer
can be up to 50%-90% [29]. In this study, there were 60
cases (78%) of HPV positive cervical SCC patients, in
which there were 32 HPV16 positive cases (42%). In
comparison with the HPV negative cervical SCC pa-
tients, miR-143 was significantly down regulated in the
HPV16 positive cervical SCC patients, suggesting that
this down regulation might be related with the carcino-
genic processes of E6 and E7 genes of HPV16. Re-
searches found that there were 53 miRNAs, including
miR-143, which were located at the gene fragile sites and
near to the HPV integration sites. Of the HPV integra-
tion sites, HPV16 integration site was the most import-
ant one [30]. The integration of HPV oncogene to the
host cell might influence the formation of miR-143 pre-
cursor. In addition, E6 gene of HPV16 could inactivate
the tumor suppressor p53, which positively regulated the
expression of miR-143 by regulating the synthesis of mature
miRNAs [31]. It was also reported that E6 gene of HPV16
could down-regulate the expression of miR-128 [32].
The traditional treatment for cervical cancer is surgery
and radiotherapy. However, the relapse rate is relatively
high and there are many complications in these methods.
NACT can enhance the efficacy of surgery and radiother-
apy, control the lesions of cervical cancer, and reduce the
lymph node metastasis rate, parametrial infiltration rate
and vascular invasion rate [6]. As previously reported,
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For example, six miRNAs, including miR-21-5p, miR-20a-
5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-
215, might be able to predict which patients benefit
from adjuvant chemotherapy [7]. The miR-143 increased
the sensitivity of human colorectal cancer cells to 5-
fluorouracil and the sensitivity of prostate cancer cells
to docetaxel [8,9]. To determine whether miR-143 is
sensitive to Taxol treatment in cervical cancer, the
changes in the expression of miR-143 and its target pro-
tein bcl-2 before and after NACT were detected in 24
patients who were treated effectively. Results showed
that there was no significant difference in the expression
of miR-143 in cervical cancer tissues after effective
chemotherapy, suggesting that miR-143 was not in-
volved in the effective response of cervical cancer tissue
to Taxol. In the 24 effective chemotherapy cases, there
was no significant decline of the bcl-2 positive expres-
sion after chemotherapy, suggesting that bcl-2, was not
involved in the response of cervical cancer tissue to
Taxol either. Taxol is able to stabilize the tubulin, in-
hibit the cell division and proliferation, and arrest the
cancer cells at G2 and M phases, thus exerting its anti-
cancer effect. The disturbance of the cell apoptosis
pathway is beneficial to the tumor growth and invasion.
Under the stimulation of cell growth factors, Rb is
phosphorylated by the G1 phase protein cyclin D, and
releases E2F, which promotes the gene transcription and
progression of cell cycle. Studies indicated that miR-143
was one of the regulating genes of cyclin D1 [33]. In
cervical cancer, miR-143 may promote apoptosis and in-
hibit tumor formation by targeting Bcl-2 [25]. Bcl-2 reg-
ulates the activation of p53 gene, and prevents the cell
from arresting at the G1 phase [34]. Thus miR-143
could regulate cell cycles directly and indirectly to in-
hibit cancer cell growth, but may not act synergetically
with Taxol. The exact relationship between miR-143 ex-
pression and cervical cancer sensitivity to Taxol still
needs further investigation.
Cervical cancer is widely recognized to be caused pri-
marily by persistent infection with high-risk HPV. How-
ever, HPV infection is not sufficient for cervical
carcinogenesis and additional genetic events are involved
in cervical carcinogenesis. It is reported that the human
telomerase gene (hTERC) is involved in the progression
of uterine cervical dysplasia to invasive cancer and can
be used for the detection of high-grade cervical intrae-
pithelial neoplasia (CIN) [35,36]. Han et al. reported that
immunoreactivities of decreased D2-40 and increased
p16INK4A were correlated with higher grade of CIN [37].
Imura et al. found that Laminin-5 was a useful bio-
marker in the evaluation of invasiveness in cervical
adenocarcinoma [38]. In this study, we analyzed the ex-
pression of miR-143, the correlation of miR-143expression with clinical pathological features of cervical
cancer, and the sensitivity of miR-143 to Taxol treat-
ment. However, the role of miR-143 expression in evalu-
ating the grade and invasiveness of cervical cancer is not
studied and still needs further investigation.
In conclusion, the down regulation of miR-143 was a
promoting factor for the occurrence of cervical SCC,
and related to the infection of HPV16. The down regula-
tion of miR-143 was also related with tumor size and
lymph node metastasis. However, miR-143 was not in-
volved in the effective responses of cervical SCC cells to
Taxol.
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